SAN DIEGO, July 7, 2014 /PRNewswire/ -- Diomics, an innovator in DNA capture technology, today announced the appointment of Thomas Kindt, Ph.D., as Diomic's chief scientific officer (CSO) effective July 7, 2014. Dr. Kindt brings more than 30 years of relevant industry experience to his new role having previously served as Director of Intramural Research of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).
"We welcome Dr. Kindt's experience and leadership to Diomics," said Mr. John Steel, CEO of Diomics. "In his new role as CSO, he will lead the discovery and enhanced product development efforts of the company. The application of X-Swab as an effective tool for low template DNA recovery for increasing yield during PCR remains a research priority for the company. Dr. Kindt's contribution to this mission will be invaluable."
"Diomics is at the forefront of DNA capture technology. Influential researchers and leading biotechnology companies in forensics and medical diagnostics are engaging with Diomic's to apply Diomat technology to capture limiting quantities of DNA," said Dr. Kindt. "I am excited to be part of Diomics, pursuing opportunities to improve DNA capture for forensics applications and as a saliva-based diagnostic for diabetes, oncology, and other high impact diseases where Diomics' platform technology enables efficient diagnosis."
Dr. Kindt was most recently the Director of Intramural Research, NIAID, NIH, Bethesda, MD, and the Chief of Laboratory of Immunogenetics, NIAID, NIH and spent a year as Visiting Scientist, Analytical Immunochemistry Laboratory at the Institute Pasteur, Paris. Prior to this he was with the Rockefeller University in New York and the City of Hope National Center in Duarte, CA. Dr. Kindt has served on advisory boards and committees of the Institute Pasteur, Tunis, Tunisia; Hematech LLC, Massachusetts; Institute for Medical Sciences, University of Tokyo; REDI Center, Singapore; NIH Facilities Working Group and Blue Ribbon Panel on Bioterrorism and Implications for Biomedical Research. He has authored and co-authored 225 publications, two books, and three patents. Currently Dr. Kindt is an active biomedical consultant, immunology textbook author, and adjunct professor at the University of New Mexico's Department of Biology.
Diomics novel technology was recently highlighted in the journal Forensic Science International: Genetics in the study, "Evaluation of a Novel Material, Diomics X-Swab, for Collection of DNA"
About Diomics, Inc.
Diomics is focused on life sciences, specifically diagnostics, forensics, integrated DNA analysis and genetic solutions. Our proprietary Diomat technology platform has the ability to efficiently pick up biologic materials from a variety of surfaces and release the majority of the DNA from the sample into the solution. The versatile characteristics of Diomat lend itself to a variety of product formats, including swabs, films, and fibers. Today based in Carlsbad, California, Diomics has developed numerous products, tools and services for the molecular diagnostic and forensic industries.
SOURCE Diomics, Inc.